130 related articles for article (PubMed ID: 33372585)
21. Clinical and molecular assessment of regorafenib monotherapy.
Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
[TBL] [Abstract][Full Text] [Related]
22. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
[TBL] [Abstract][Full Text] [Related]
23. Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients.
Schvartsman G; Wagner MJ; Amini B; Zobniw CM; Trinh VA; Barbo AG; Lin HY; Wang WL; Conley AP; Ravi V; Araujo DM; Zarzour MA; Benjamin RS; Patel S; Somaiah N
Sci Rep; 2017 Aug; 7(1):9519. PubMed ID: 28842575
[TBL] [Abstract][Full Text] [Related]
24. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
Sun W; Patel A; Normolle D; Patel K; Ohr J; Lee JJ; Bahary N; Chu E; Streeter N; Drummond S
Cancer; 2019 Mar; 125(6):902-909. PubMed ID: 30561756
[TBL] [Abstract][Full Text] [Related]
25. [Regorafenib in patients with metastatic colorectal cancer: a review and an update].
Zaniboni A; Mansueto G
Recenti Prog Med; 2015 Dec; 106(12):629-33. PubMed ID: 26780072
[TBL] [Abstract][Full Text] [Related]
26. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
[TBL] [Abstract][Full Text] [Related]
27. Improving patient outcomes with regorafenib for metastatic colorectal cancer - patient selection, dosing, patient education, prophylaxis, and management of adverse events.
Hofheinz RD; Arnold D; Kubicka S; Prasnikar N; Vogel A
Oncol Res Treat; 2015; 38(6):300-8. PubMed ID: 26045027
[TBL] [Abstract][Full Text] [Related]
28. Regorafenib in metastatic colorectal cancer.
Grothey A
Clin Adv Hematol Oncol; 2012 May; 10(5):324-5. PubMed ID: 22706543
[No Abstract] [Full Text] [Related]
29. Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
Callebout E; Ribeiro SM; Laurent S; De Man M; Ferdinande L; Claes KBM; Van der Meulen J; Geboes KP
BMC Cancer; 2019 Jun; 19(1):567. PubMed ID: 31185985
[TBL] [Abstract][Full Text] [Related]
30. Capecitabine plus temozolomide (CapTem): An alternative regimen to regorafenib as third-line setting in metastatic colorectal cancer?
Ergun Y; Bal O; Dogan M; Uncu D
J BUON; 2019; 24(6):2435-2441. PubMed ID: 31983117
[TBL] [Abstract][Full Text] [Related]
31. Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND).
Bozzarelli S; Rimassa L; Giordano L; Sala S; Tronconi MC; Pressiani T; Smiroldo V; Prete MG; Spaggiari P; Personeni N; Santoro A
Future Oncol; 2019 Dec; 15(35):4009-4017. PubMed ID: 31746632
[No Abstract] [Full Text] [Related]
32. Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
Masuishi T; Taniguchi H; Hamauchi S; Komori A; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
Clin Colorectal Cancer; 2017 Jun; 16(2):e15-e22. PubMed ID: 27670892
[TBL] [Abstract][Full Text] [Related]
33. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study.
Kim JH; Kim SY; Kim KP; Kim TW; Chae SY; Kim HJ; Kim JS; Ryu JS; Moon DH; Kim JE; Hong YS
Target Oncol; 2019 Dec; 14(6):689-697. PubMed ID: 31555963
[TBL] [Abstract][Full Text] [Related]
34. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Wong M; Strickland A; Kim JW; Zalcberg JR; Simes J; Goldstein D
J Clin Oncol; 2016 Aug; 34(23):2728-35. PubMed ID: 27325864
[TBL] [Abstract][Full Text] [Related]
35. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
37. Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies.
Draper A
Oncology (Williston Park); 2019 Apr; 33(4):126-7. PubMed ID: 30990563
[No Abstract] [Full Text] [Related]
38. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy.
Angeles A; Hung W; Cheung WY
Med Oncol; 2018 Jun; 35(8):114. PubMed ID: 29936654
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.
Fukuoka S; Shitara K; Noguchi M; Kawazoe A; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
Clin Colorectal Cancer; 2017 Jun; 16(2):e39-e44. PubMed ID: 27780748
[TBL] [Abstract][Full Text] [Related]
40. Regorafenib- associated panniculitis.
Chockalingam R; Aung P; Patel AB
Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
